Share This Page
Litigation Details for Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals, Inc. (D. Del. 2025)
✉ Email this page to a colleague
Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals, Inc. (D. Del. 2025)
| Docket | ⤷ Start Trial | Date Filed | 2025-07-24 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory B. Williams |
| Jury Demand | None | Referred To | |
| Patents | 8,580,304; 9,155,706; 9,271,941; 9,399,021 | ||
| Attorneys | Alexandra M. Joyce | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals, Inc.
Details for Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals, Inc. (D. Del. 2025)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2025-07-24 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Novartis v. Teva (1:25-cv-00928): Litigation Summary and Patent Exposure Analysis
Executive summary
The docket Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals, Inc., 1:25-cv-00928 is filed in federal court and is expected to concern IP infringement tied to an FDA application (typical Paragraph IV or related declaratory-judgment structure). A complete litigation summary requires case caption details, asserted patent numbers, procedural posture, and claim charts or settlement terms. These core record elements are not provided here, so no accurate infringement, timeline, or strength analysis can be produced without fabrication.
What is case 1:25-cv-00928 about?
Answer: The case name and parties indicate a patent infringement dispute between Novartis and Teva, but the specific asserted patents, drug product, and FDA linkage are not stated in the provided information, so the subject matter cannot be identified reliably.
What court and jurisdiction governs 1:25-cv-00928?
Answer: The case number shows a federal matter (civil action format “1:25-cv-00928”), but the district, judge, and case type are not provided, so procedural analysis cannot be completed.
What triggers the lawsuit: Paragraph IV, 505(b)(2), or other?
Answer: Patent cases involving Teva and Novartis commonly arise from Hatch-Waxman filings and Orange Book listings, but this cannot be confirmed for 1:25-cv-00928 without the complaint allegations or FDA application paragraph.
Which patents does Novartis assert against Teva in 1:25-cv-00928?
Answer: The asserted patent numbers are not provided, so the patent estate cannot be mapped.
How to identify the asserted claims driving the dispute
Answer: The specific asserted claims (independent claims on composition, formulation, or method-of-use; and dependent claims on stability or manufacturing) depend on the complaint’s claim listing and infringement chart. Those details are not available here.
How many patents are typically asserted in Novartis–Teva Hatch-Waxman actions?
Answer: This varies by product and formulation strategy. A numeric estimate without asserted-patent data would be speculative.
What is the litigation timeline for 1:25-cv-00928?
Answer: No procedural dates are provided (complaint filing date, service date, responsive pleading deadline, Markman schedule, claim construction hearing, discovery cutoff, trial date, or dispositive motion deadlines).
What milestones typically appear on the docket
Answer: In patent infringement dockets, key milestones often include:
- complaint and summons
- answer or motion to dismiss
- claim construction scheduling order
- preliminary injunction briefing (if sought)
- infringement and invalidity expert reports
- summary judgment motions
- trial or settlement
No docket entries are included here, so no accurate timeline can be produced.
What is the current procedural posture of Novartis v. Teva (1:25-cv-00928)?
Answer: Current posture cannot be determined because no docket status (e.g., pending motion to dismiss, stay pending ITC, claim construction completed, settlement filed) is provided.
Is the case likely stayed or consolidated?
Answer: Consolidation or stay depends on related actions and judicial orders. No such information is included.
What defenses does Teva raise in 1:25-cv-00928?
Answer: Teva’s defenses typically include non-infringement, invalidity (35 USC §§ 102/103/112), lack of § 271(e)(2) act of infringement for the relevant claims, or procedural defenses. Those arguments cannot be enumerated for 1:25-cv-00928 without the motion papers or responsive pleading.
What invalidity theories matter most for generic entry risk?
Answer: For high-stakes exposure, parties focus on:
- anticipation/obviousness based on prior art references
- indefiniteness or lack of enablement for claim scope
- prosecution history estoppel (if relevant)
No asserted patents or claim scope are provided, so no theory-by-theory assessment is possible.
How strong is Novartis’s patent case in 1:25-cv-00928?
Answer: Strength cannot be measured without:
- asserted patents
- relevant claim construction positions
- prior art record
- Teva’s non-infringement and invalidity contentions
- any early rulings (e.g., denial of a motion to dismiss)
What would “strength” depend on in this dispute?
Answer: For Hatch-Waxman, strength generally depends on:
- defensibility of composition/formulation claims against design-arounds
- whether method-of-use claims are implicated by labeling or proposed instructions for use
- validity resilience against key prior art
Those factors require the missing claim and patent data.
Does 1:25-cv-00928 include a request for injunction or expedited relief?
Answer: Injunctive relief depends on the complaint and any preliminary injunction filings. No pleadings or docket entries are provided.
What is the practical effect if an injunction is sought?
Answer: If granted, it can delay FDA approval and launch. This effect cannot be predicted without knowing whether the plaintiff sought it and whether the court set deadlines.
How does this case affect Teva’s generic or biosimilar launch strategy?
Answer: The launch impact depends on:
- the drug and dosage form tied to the asserted patents
- the Orange Book patent list and exclusivity calendar
- whether a settlement triggers a “design-around” or a launch-date license
None of these are included in the provided input.
Are there any settlement signals in 1:25-cv-00928?
Answer: No settlement terms or docket indicators are provided.
What settlements typically include in Novartis–Teva disputes
Answer: Common terms include:
- early or delayed launch dates
- stipulated non-infringement positions
- covenant not to sue for certain activities
- patent licenses or royalty-bearing structures
No settlement record exists in the information given.
What FDA regulatory pathway is implicated by this litigation?
Answer: FDA pathway cannot be identified without the drug’s name, NDA/ANDA number, and the paragraph in the notice letter.
Orange Book and 180-day exclusivity risk
Answer: Exclusivity risk analysis requires the Orange Book patent list and whether any generic competitor holds 180-day exclusivity. That dataset is not provided here.
How does this litigation compare with other Novartis vs. Teva patent cases?
Answer: Comparison requires at least one of: asserted patents, the drug identity, or prior outcomes. With none provided, no accurate comparison is possible.
Key case identifiers to extract from the docket (what matters for IP risk)
Answer: For business and litigation control, the following docket artifacts are decisive but are not supplied:
- complaint: asserted patent numbers, infringement theory, and asserted claims
- Teva’s answer: asserted counterclaims and defenses
- claim construction schedule: Markman issues and the court’s early orders
- any PTAB-related filings: IPR/PGR timelines affecting validity posture
- settlement or consent judgment entries
Key Takeaways
- The docket identifier (1:25-cv-00928) and parties (Novartis v. Teva) are known, but the asserted patents, drug identity, FDA linkage, and procedural posture are not provided.
- Without those elements, any litigation “summary and analysis” would require assumptions and would be unreliable.
FAQs
What is the fastest way to determine what patents are asserted in 1:25-cv-00928?
Answer: Review the complaint for the patent numbers and asserted claims and match them to Orange Book listings for the relevant NDA/ANDA.
Does the case involve paragraph IV certifications?
Answer: Determine by checking the FDA linkage stated in the complaint and any referenced Hatch-Waxman notice letter.
Will claim construction likely decide the case early?
Answer: Patent claim scope often drives outcome, but this depends on the court’s schedule and early Markman rulings, which are not provided.
Could IPR petitions at the PTAB affect 1:25-cv-00928?
Answer: They can, but the existence and timing of PTAB filings must be confirmed from docket records and PTAB captions.
What commercial outcome should be modeled for Teva if an injunction is granted?
Answer: Modeling requires the launch-ability of the specific Teva product, which depends on the FDA approval status and the injunctive reach tied to asserted claims.
References
- Not provided in the input.
More… ↓
